We are live on ! Find out more

Quest Diagnostics

DGX

Market cap $26.2B

237.20 USD

+3.77

1.62%

At close Updated Oct 15, 12:39 PM EDT

1 day

1.62%

5 days

4.1%

1 month

-4%

3 months

17.56%

6 months

23.92%

Year to date

36.49%

1 year

26.61%

5 years

66.46%

10 years

185.65%

About: Quest Diagnostics is a leading independent provider of diagnostic testing, information, and services in the US. The company generates over 97% of its revenue through clinical testing, anatomic pathology, esoteric testing, and substance abuse testing with specimens collected at its national network of roughly 2,400 patient service centers, as well as multiple doctors offices and hospitals. The firm also runs a much smaller diagnostic solutions segment that provides clinical trials testing, risk-assessment services, and information technology solutions.

Employees: 57,000

Healthcare Diagnostics & Research

News

Positive

Neutral

Negative

Sentiment 3-Months

Positive 54.5%

Neutral 41.8%

Negative 3.6%

Zacks Investment Research

Here's How Quest Diagnostics Is Placed Ahead of Q3 Earnings

DGX heads into Q3 earnings with expected revenue and EPS growth, fueled by strong clinical demand, advanced diagnostics and operational efficiencies.

Here's How Quest Diagnostics Is Placed Ahead of Q3 Earnings

Zacks Investment Research

Here's Why Quest Diagnostics (DGX) is a Strong Value Stock

Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.

Here's Why Quest Diagnostics (DGX) is a Strong Value Stock

Dividend Champion, Contender, And Challenger Highlights: Week October 4

A weekly summary of dividend activity for Dividend Champions, Contenders, and Challengers. Companies which changed their dividends. Companies with upcoming ex-dividend dates.

Dividend Champion, Contender, And Challenger Highlights: Week October 4

Haystack MRD® Demonstrates Robust Clinical Performance in Specimen Cohort from the Landmark DYNAMIC Colorectal Cancer Trials

Test showed 100% specificity, with no false-positive results in the cohort, at both 3- and 5-year follow-up, and sensitivity of 100% and 83.3%, respectively, for predicting disease recurrence SECAUCUS, N.J., Oct. 1, 2026 /PRNewswire/ -- A new study published in The Journal of Molecular Diagnostics showed that the Haystack MRD® test is highly accurate at detecting residual and recurrent disease, demonstrating clinical performance in specimens from the landmark DYNAMIC colorectal cancer trial series.

Haystack MRD® Demonstrates Robust Clinical Performance in Specimen Cohort from the Landmark DYNAMIC Colorectal Cancer Trials

Zacks Investment Research

Quest Diagnostics Stock Gains 36.3% YTD: What's Behind the Rally?

DGX's 36.3% YTD rise reflects momentum in advanced diagnostics, channel growth, AI adoption and cost savings.

Quest Diagnostics Stock Gains 36.3% YTD: What's Behind the Rally?

Zacks Investment Research

Why Quest Diagnostics (DGX) is a Top Value Stock for the Long-Term

Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.

Why Quest Diagnostics (DGX) is a Top Value Stock for the Long-Term

Quest Diagnostics Incorporated: Testing Growth Keeps Me Bullish Despite Medicare Headwinds

Quest Diagnostics Incorporated's recurring testing demand provides a foundation for growth through hospital partnerships, dialysis services, and advanced diagnostics. Their dialysis testing and advanced diagnostics add growth opportunities, although their value ultimately depends on execution and reimbursement. So far, DGX's cash flows seem to be benefiting from the acquisition strategy, but if this falters, it may lead to write-downs of its sizable goodwill on the balance sheet.

Quest Diagnostics Incorporated: Testing Growth Keeps Me Bullish Despite Medicare Headwinds

Quest Diagnostics to Release Third Quarter Financial Results on October 22, 2026

SECAUCUS, N.J., Sept. 22, 2026 /PRNewswire/ -- Quest Diagnostics Incorporated (NYSE: DGX), a leader in diagnostic information services, announced today that it will report its third quarter 2026 financial results on Thursday, October 22, 2026, before the market opens.

Quest Diagnostics to Release Third Quarter Financial Results on October 22, 2026

The Motley Fool

Why Quest Diagnostics Holdings Stock Dropped Today

Medicare and Medicaid have been overpaying Quest Diagnostics for years, says the government. Starting next year, they plan to cut reimbursement of lab testing by 15%.

Why Quest Diagnostics Holdings Stock Dropped Today

Zacks Investment Research

Quest Diagnostics Study Finds High Tick-Borne Disease Co-Exposure

DGX study finds nearly one-third of Lyme-seropositive patients had antibodies to another tick-borne pathogen, highlighting broader testing needs.

Quest Diagnostics Study Finds High Tick-Borne Disease Co-Exposure

See News Rankings

Price charts implemented using Lightweight Charts™